All In Biotech

Drug Trial Radar · NCT04102579

Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

Last checked: Nov 20, 2026Latest source record: Oct 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

128

Actual

Start

Nov 13, 2019

Primary completion

Oct 15, 2021

Study completion Oct 26, 2021

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
Collaborators
Huntington Study Group
First posted
Sep 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in participants with Huntington disease.

Conditions

  • Chorea, Huntington

Interventions

  • ValbenazineDrug

    vesicular monoamine transporter 2 (VMAT2) inhibitor

  • PlaceboDrug

    non-active dosage form

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Screening Period Baseline to Maintenance Period in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) Score.Time frame: Baseline (average of screening and Day -1), maintenance (average of Weeks 10 and 12)

Locations

46 sites in 2 countries. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Birmingham, Alabama

  • Neurocrine Clinical Site

    Little Rock, Arkansas

  • Neurocrine Clinical Site

    La Jolla, California

  • Neurocrine Clinical Site

    Sacramento, California

  • Neurocrine Clinical Site

    Aurora, Colorado

  • Neurocrine Clinical Site

    Englewood, Colorado

  • Neurocrine Clinical Site

    Washington D.C., District of Columbia

  • Neurocrine Clinical Site

    Gainesville, Florida

  • Neurocrine Clinical Site

    Miami, Florida

  • Neurocrine Clinical Site

    Atlanta, Georgia

  • Neurocrine Clinical Site

    Chicago, Illinois

  • Neurocrine Clinical Site

    Chicago, Illinois

  • Neurocrine Clinical Site

    Indianapolis, Indiana

  • Neurocrine Clinical Site

    Iowa City, Iowa

  • Neurocrine Clinical Site

    Kansas City, Kansas

  • Neurocrine Clinical Site

    Wichita, Kansas

  • Neurocrine Clinical Site

    Louisville, Kentucky

  • Neurocrine Clinical Site

    New Orleans, Louisiana

  • Neurocrine Clinical Site

    Boston, Massachusetts

  • Neurocrine Clinical Site

    Boston, Massachusetts

  • Neurocrine Clinical Site

    Charlestown, Massachusetts

  • Neurocrine Clinical Site

    Ann Arbor, Michigan

  • Neurocrine Clinical Site

    West Bloomfield, Michigan

  • Neurocrine Clinical Site

    Omaha, Nebraska

  • Neurocrine Clinical Site

    Rochester, New York

  • Neurocrine Clinical Site

    Williamsville, New York

  • Neurocrine Clinical Site

    Durham, North Carolina

  • Neurocrine Clinical Site

    Fargo, North Dakota

  • Neurocrine Clinical Site

    Cleveland, Ohio

  • Neurocrine Clinical Site

    Columbus, Ohio

  • Neurocrine Clinical Site

    Toledo, Ohio

  • Neurocrine Clinical Site

    Pittsburgh, Pennsylvania

  • Neurocrine Clinical Site

    Charleston, South Carolina

  • Neurocrine Clinical Site

    Columbia, South Carolina

  • Neurocrine Clinical Site

    Greenville, South Carolina

  • Neurocrine Clinical Site

    Nashville, Tennessee

  • Neurocrine Clinical Site

    Houston, Texas

  • Neurocrine Clinical Site

    Salt Lake City, Utah

  • Neurocrine Clinical Site

    Burlington, Vermont

  • Neurocrine Clinical Site

    Charlottesville, Virginia

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.